COSMO Pharmaceuticals SA

Price Chart

Risk-Adjusted Performance

Also Listed On

COSMO Pharmaceuticals SA (COPN) Price Performance

COSMO Pharmaceuticals SA (COPN) trades on SIX Swiss Exchange in CHF. The company is classified in the Healthcare sector under the Drug Manufacturers - General industry. The stock currently trades at CHF97.80, up 1.35% from the previous close.

Over the past year, COPN has traded between a low of CHF42.28 and a high of CHF124.80. The stock has gained 121.0% over this period. It is currently 21.6% below its 52-week high.

COSMO Pharmaceuticals SA has a market capitalization of $1.68B, with a price-to-earnings ratio of 19.73 and a dividend yield of 2.18%.

About COSMO Pharmaceuticals SA

Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers budesonide directly to the lumen of the colon; Eleview, an injectable composition to allow endoscopists with excision of gastrointestinal lesions; Lumeblue, a diagnostic drug for the visualisation of colorectal lesions during colonoscopies; Aemcolo/Rifamycin, a pharmaceutical drug product in form of tablets that is approved for the treatment of travelers' diarrhoea; and Clascoterone, which is in phase-3 clinical trial for the treatment of male pattern hair loss. It is also developing novel UC treatment, which is in phase-2 clinical trial for the treatment of distal inflammatory bowel disease/distal ulcerative colitis/proctitis; BAD Treatment (CB-01-33), which is in phase-2 clinical trial for the treatment of colesevelam formulation/bile acid diarrhea; and CB-03-10, which is in phase-1 clinical trial for the treatment of oncology solid tumors, as well as provides Cosmo's AI technology, a GI Genius intelligent endoscopy system. The company was formerly known as Cosmo Pharmaceuticals N.V. and changed its name to Cosmo N.V. in April 2026. The company was founded in 1997 and is headquartered in Dublin, Ireland.